We serve Chemical Name:(s)-4,4,4-trifluorobutane-1,3-diol CAS:135154-88-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(s)-4,4,4-trifluorobutane-1,3-diol
CAS.NO:135154-88-0
Synonyms:s-tfbdol
Molecular Formula:C4H7F3O2
Molecular Weight:144.09200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:188.1ºC at 760mmHg
Density:1.354g/cm3
Index of Refraction:1.37
PSA:40.46000
Exact Mass:144.04000
LogP:0.29200
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like s-tfbdol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,s-tfbdol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,s-tfbdol Use and application,s-tfbdol technical grade,usp/ep/jp grade.
Related News: Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. (s)-4,4,4-trifluorobutane-1,3-diol manufacturer With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. (s)-4,4,4-trifluorobutane-1,3-diol supplier The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development. (s)-4,4,4-trifluorobutane-1,3-diol vendor Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. (s)-4,4,4-trifluorobutane-1,3-diol factory By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.
